FDA Brief

Warning letters Drugs

FDA warning letter to

Maison Terre, LLC

High riskIssued Apr 1, 2021Posted Apr 13, 2021Office of Pharmaceutical Quality Operations, Division II

FDA says Maison Terre repacked Goldenseal Root Powder under insanitary conditions with microbial contamination and sold unapproved drug products.

What happened

FDA tested "Goldenseal Root Powder Organic" collected at the firm's facility and found high microbial counts plus objectionable organisms including Enterobacter cloacae, Klebsiella pneumoniae, and Cronobacter sakazakii. The letter says the product was repacked in residential kitchen and living spaces, and FDA reviewed website and Facebook claims showing the goldenseal and two essential oils were offered as unapproved drugs. The firm recalled the goldenseal nationwide on August 17, 2020.

What FDA found

  1. The firm prepared, packed, or held Goldenseal Root Powder Organic under insanitary conditions in shared residential spaces, risking filth contamination.

    FD&C Act section 501(a)(2)(A), 21 U.S.C. 351(a)(2)(A)
  2. The firm did not test each batch of its drug product for objectionable microorganisms.

    21 CFR 211.165(b)
  3. The firm did not test incoming goldenseal root powder lots for objectionable microbial contamination before use.

    21 CFR 211.84(d)(6)
  4. The firm lacked a quality control unit with authority to approve or reject components and drug products.

    21 CFR 211.22(a)
  5. The firm lacked separate or defined areas or controls to prevent contamination and mix-ups.

    21 CFR 211.42(c)
  6. The firm marketed Goldenseal Root Powder Organic and two essential oils as unapproved new drugs and without adequate directions for use.

    FD&C Act sections 505(a) and 502(f)(1), 21 U.S.C. 355(a) and 352(f)(1)

What FDA wants

Respond in writing within 15 working days describing corrective actions and preventing recurrence, and clarify whether the firm intends to resume manufacturing drugs at the facility.

Who should pay attention

  • retailers and online marketplaces selling herbal powders
  • consumers who use goldenseal on broken skin or on infants
  • companies that repack or buy botanical drug ingredients

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk